Risk factors
Moleculin Biotech (MBRX) risk factors
Item 1A of every Moleculin Biotech, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
82 risks, 17 new, 9 dropped, 13 reworded since the prior year. Moleculin faces intense dependency on single-source suppliers for drug candidates like Annamycin and requires continuous external funding to survive.
Filed Mar 18, 2026 - FY2024 10-K risk factors
74 risks. Moleculin Biotech operates as a clinical-stage pharmaceutical company with no approved products, relying heavily on third-party manufacturers, physician-sponsored trials, and additional funding to advance its oncology pipeline.
Filed Mar 21, 2025